Keeping Connectivity Within Reach, OPPO Launches Its First Smartwatch With Thales’ eSIM Solutions
OPPO, the world's leading smart device manufacturer, has selected Thales’ set of eSIM products and services for its OPPO Watch, the brand’s first smartwatch series with built-in cellular connectivity. The launch of the OPPO Watch marks a strategic step into the field of IoT for the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200906005025/en/
OPPO Watch © OPPO
One of the most compelling features of the OPPO Watch is the eSIM-based cellular connectivity. Thales’ eSIM allows OPPO Watch users to enjoy a smoothly digital experience by activating a mobile subscription remotely and always stay connected without having to tether it to a mobile phone. Users can make voice calls or send messages at any time directly through the smartwatch, providing seamless connectivity during workouts or other situations where carrying a mobile phone is inconvenient. This smooth experience leverages Thales eSIM solutions to offer a full range of subscription services during the life cycle of the device.
By eliminating the need for an additional SIM card slot, Thales’ eSIM makes sleek mobile-connected smartwatches possible. Indeed it enables a thinner and lighter smartwatch design while freeing up more space for extra features such as up to 50 meter water resistance. It thereby helps OPPO fulfil its mission of elevating life through technological artistry.
The Thales embedded SIM has been qualified by all three China’s mobile operators allowing OPPO smartwatch users to select their mobile subscription from any of these operators.
“As OPPO's first foray into the wearable electronics market, the OPPO Watch marks a strategic step into the field of AIoT (Artificial IoT) for the company. Thanks to Thales' eSIM solutions that bring smartphone-level convenience to smartwatches, users can stay connected in a smarter and more efficient way without restrictions. We are looking forward to working with Thales again, given their leadership in eSIM and the success of our current partnership.”
Liu Bo, President of OPPO China
“The wearable segment is the second largest market for eSIM-compliant consumer electronics after smartphones. ABI Research forecasts that a total of 315 million cellular enabled wearables will have shipped by 2025. Smartwatch makers, in particular, are increasingly on-boarding eSIM connectivity in their flat-design devices to address new smartwatch-only use cases such as kids safety, sports and health monitoring...”
David McQueen, Director, Connected Consumer Devices, ABI ResearchResearch
“Thales is honoured to provide a full suite of eSIM solutions for OPPO Watch. AIoT is one of OPPO’s key focuses aiming to bring customers seamless experiences to their daily life, including sport and health. Thales is OPPO’s key eSIM solutions partner, empowering them with instant connectivity for their consumer devices. We are proud to accompany OPPO on this journey and fully support their ambitions of providing their users with the best innovations available.”
Jérôme Bendell, Vice President of Thales North Asia and CEO of Thales in China
Thales is the world's leader in eSIM connectivity management with more than 200 eSIM management platforms awarded by mobile operators, operator alliances, MVNOs, automotive makers, and OEMs across all continents.
Related resources:
What is an eSIM: 6 illustrated answers infographic
4 ways to activate eSIM-capable consumer IoT devices dossier
Best practices for optimising eSIM adoption eBook
Innovative eSIM use cases such as prepaid offers for inbound travelers and family bundledossier
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations – connectivity, Big Data, artificial intelligence and cybersecurity – technologies that support businesses, organisations and governments in their decisive moments.
About Thales in China
Thales provides innovative solutions for the infrastructure that forms the backbone of China’s growth. The Group has been present in China for around 40 years and is the trusted partner for the Chinese aviation and urban rail transportation industries. In the meanwhile, from secure software to biometrics and encryption, Thales has successfully applied its advanced technology to mobile communication, banking, IoT and software monetization etc. Thales has 3 JVs and employs 2,300 people with offices located in 8 cities in China. Thales established R&D centers and Innovation Hubs in Beijing, Dalian and Hong Kong to provide innovative solutions for both China and international market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200906005025/en/
Contact information
PRESS
Head of Government Affairs & Communications
Thales in China
Tammy Qiu
+86 10 65875066
tammy.qiu@asia.thalesgroup.com
Thales, Media Relations
Digital Identity & Security
Vanessa Viala
+33 6 07 34 00 34
vanessa.viala@thalesgroup.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom